2018
DOI: 10.1002/bmc.4140
|View full text |Cite
|
Sign up to set email alerts
|

Determination of telbivudine in the plasma of chronic hepatitis B patients in long‐term treatment by high‐performance liquid chromatographic–tandem mass spectrometry

Abstract: Creatine kinase elevation is commonly reported in telbivudine-treated patients. However, little is known about the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC-MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B patients. The assay was linear in a dynamic 10-10,000 ng/mL range (r > 0.999) and total analysis time was 6 min in this method. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“… Drugs name Method Chromatographic conditions LOD (ng/mL) Linear range (ng/mL) Matrices Ref. Mode Stationary phase Mobile phase Telbivudine LC-MS/MS MRM ESI + C18 (100 × 3.0 mm, 3 μm) A: 0.1% Formic acid in purified water (v/v) NM 10–10000 Plasma [ 108 ] B: Acetonitrile Sofosbuvir UPLC- MS/MS MRM ESI + C18 (50 × 4.6 mm, 5 μm) 0.5% Formic acid: Methanol (30:70, v/v) NM 4.063–8000 Plasma [ 109 ] Sofosbuvir UPLC- MS/MS MRM ESI C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile-0.1% formic acid (50:50, v/v) NM 0.25–3500 Plasma [ 110 ] Sofosbuvir and GS-331007 UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile:5 mM ammonium formate: 0.1% formic acid (85:15:0.1% v/v/v) 0.35 1–1000 Plasma [ 111 ] 3 10–1500 Sofosbuvir and GS-331007 UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.8 μm) 0.1% Formic acid and acetonitrile (50:50, v/v) NM 10–2500 Plasma [ 112 ] Sofosbuvir and Velpatasvir UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile-0.1% formic acid (50: 50, v/v) NM 0.25–3500 Plasma ...…”
Section: Chromatographic Techniquesmentioning
confidence: 99%
“… Drugs name Method Chromatographic conditions LOD (ng/mL) Linear range (ng/mL) Matrices Ref. Mode Stationary phase Mobile phase Telbivudine LC-MS/MS MRM ESI + C18 (100 × 3.0 mm, 3 μm) A: 0.1% Formic acid in purified water (v/v) NM 10–10000 Plasma [ 108 ] B: Acetonitrile Sofosbuvir UPLC- MS/MS MRM ESI + C18 (50 × 4.6 mm, 5 μm) 0.5% Formic acid: Methanol (30:70, v/v) NM 4.063–8000 Plasma [ 109 ] Sofosbuvir UPLC- MS/MS MRM ESI C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile-0.1% formic acid (50:50, v/v) NM 0.25–3500 Plasma [ 110 ] Sofosbuvir and GS-331007 UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile:5 mM ammonium formate: 0.1% formic acid (85:15:0.1% v/v/v) 0.35 1–1000 Plasma [ 111 ] 3 10–1500 Sofosbuvir and GS-331007 UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.8 μm) 0.1% Formic acid and acetonitrile (50:50, v/v) NM 10–2500 Plasma [ 112 ] Sofosbuvir and Velpatasvir UPLC- MS/MS MRM ESI + C18 (50 × 2.1 mm, 1.7 μm) Acetonitrile-0.1% formic acid (50: 50, v/v) NM 0.25–3500 Plasma ...…”
Section: Chromatographic Techniquesmentioning
confidence: 99%
“…Conventional instrumental analyses, such as gas chromatography (Li et al, 2013;Mishra et al, 2017), high performance liquid chromatography (Chen et al, 2018;Ding et al, 2018;Gao et al, 2018;Sampaio Teixeira et al, 2018), and liquid chromatography-tandem mass spectrometry (Gao et al, 2017;Hasan et al, 2016;Oswald et al, 2011;Vu et al, 2014), are sensitive and accurate detection methods, but they are time consuming and need highly qualified personnel to run, and are expensive (Ge et al, 2018;Hao et al, 2018;Zhou et al, 2020).…”
Section: Introductionmentioning
confidence: 99%